Table 1. Demographic characteristics and clinicopathological variables of 99 Arab patients with colorectal cancer a matched 99 Western patients.
| Characteristic | Arab patients (N=99) (%) | Western patients (N=99) (%) |
|---|---|---|
| Sex (%) | ||
| Male | 60 (60.6) | 61 (61.6) |
| Female | 39 (39.4) | 38 (38.4) |
| Testing type (%) | ||
| 46 genes | 38 (38.4) | 38 (38.4) |
| 50 genes | 61 (61.6) | 61 (61.6) |
| Age at diagnosis (mean ± SD) [range] | ||
| All | 50.80±13.62 [20–77] | 48.03±12.50 [20–79] |
| Male | 52.70±14.60 | 50.10±13.30 |
| Female | 47.80±11.50 | 44.60±10.30 |
| Age* (years) (%) | ||
| ≤50 | 47 (47.5) | 47 (47.5) |
| >50 | 52 (52.5) | 52 (52.5) |
| The distribution of patients from the six Arab Gulf countries (%) | ||
| Saudi Arabia | 39 | – |
| United Arab Emirates | 34 | – |
| Kuwait | 11 | – |
| Qatar | 7 | – |
| Bahrain | 2 | – |
| Oman | 2 | – |
| Not available | 5 | – |
| Race among Western patients (%) | ||
| White | – | 79 (79.8) |
| Black African American | – | 11 (11.1) |
| Hispanic | – | 9 (9.1) |
| Primary tumor site (side of body)** (%) | ||
| Left sided | 69 (69.7) | 64 (64.6) |
| Right sided | 24 (24.2) | 35 (35.4) |
| Unknown (missing data) | 6 (6.1) | – |
| Primary tumor site (specific location)** (%) | ||
| Ascending colon | 9 (9.1) | 7 (7.1) |
| Cecum | 7 (7.1) | 18 (18.2) |
| Hepatic flexure | 1 (1.0) | 4 (4.0) |
| Splenic flexure | 1 (1.0) | 2 (2.0) |
| Transverse colon | 5 (5.0) | 4 (4.0) |
| Descending colon | 6 (6.0) | 15 (15.2) |
| Sigmoid colon | 27 (27.3) | 18 (18.2) |
| Rectum | 37 (37.4) | 31 (31.3) |
| Unknown (missing data) | 6 (6.1) | – |
| Histological type** (%) | ||
| Tubular adenocarcinoma | 83 (83.8) | 93 (94.0) |
| Mucinous adenocarcinoma | 10 (10.1) | 6 (6.0) |
| Unknown (missing data) | 6 (6.1) | – |
| Tumor differentiation** (%) | ||
| Well | 5 (5.1) | 2 (2.1) |
| Moderate | 66 (66.6) | 79 (84.1) |
| Poor | 22 (22.2) | 13 (13.8) |
| Unknown (missing data) | 6 (6.1) | – |
| TNM stage** (%) | ||
| I | 0 | 3 (3.1) |
| II | 3 (3.0) | 6 (6.1) |
| III | 41 (41.4) | 15 (15.3) |
| IV | 49 (49.5) | 74 (75.5) |
| Unknown (missing data) | 6 (6.1) | – |
| KRAS mutation (%) | ||
| Positive | 44 (44.4) | 48 (48.4) |
| Negative | 55 (55.6) | 51 (51.6) |
| NRAS mutation (%) | ||
| Positive | 4 (4.0) | 4 (4.0) |
| Negative | 95 (96.0) | 95 (96.0) |
| BRAF mutation (%) | ||
| Positive | 4 (4.0) | 4 (4.0) |
| Negative | 95 (96.0) | 95 (96.0) |
| TP53 mutation (%) | ||
| Positive | 52 (52.5) | 47 (47.5) |
| Negative | 47 (47.5) | 52 (52.5) |
| APC mutation (%) | ||
| Positive | 27 (27.3) | 24 (24.2) |
| Negative | 72 (72.7) | 75 (75.8) |
*, for 1 patient (1%), age of diagnosis was not available; **, for 6 patients (6.1%), data were not available for the primary tumor site, histological type, tumor differentiation, and TNM stage.